Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134154 | 0.91 | HRH3 (0.44) | HRH3ESR1ESR2MEN1KMT2A | |
| SCHEMBL6134157 | 0.91 | HRH3 (0.44) | HRH3ESR1ESR2MEN1KMT2A | |
| SCHEMBL6134442 | 0.86 | HRH3 (0.55) | HRH3ESR1ESR2MEN1KMT2A | |
| SCHEMBL6135132 | 0.85 | HRH3 (0.56) | HRH3ESR1ESR2MEN1KMT2A | |
| SCHEMBL6134222 | 0.83 | HRH3 (0.53) | HRH3ESR1ESR2MEN1KMT2A | |
| SCHEMBL6134406 | 0.83 | HRH3 (0.53) | HRH3ESR1ESR2MEN1KMT2A | |
| SCHEMBL6134823 | 0.83 | HRH3 (0.38) | HRH3GPR119MAPT | |
| SCHEMBL6135547 | 0.82 | HRH3 (0.52) | HRH3ESR1ESR2MEN1KMT2A | |
| SCHEMBL6133752 | 0.79 | MEN1 (0.39) | HRH3ESR1ESR2MEN1KMT2A | |
| SCHEMBL6133750 | 0.79 | MEN1 (0.39) | HRH3ESR1ESR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| WO-2004113368-A1 | CYCLIC LIPOPEPTIDES | ASTELLAS PHARMA INC. (JP) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | MAN2B1, MAN2A1, MANBA | HRH3 2668/4885ESR1 4816/4885ESR2 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.